Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-SIRP alpha Antibody-PE (8I335) is a PE-conjugated Mouse antibody targeting SIRP alpha. Anti-SIRP alpha Antibody-PE (8I335) can be used in FCM.
Description | Anti-SIRP alpha Antibody-PE (8I335) is a PE-conjugated Mouse antibody targeting SIRP alpha. Anti-SIRP alpha Antibody-PE (8I335) can be used in FCM. |
Ig Type | Monoclonal Mouse IgG2b |
Clone | 8I335 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of anti-human SIRPa (CD172a) on human whole blood monocytes. Human monocytess were stained with PE-anti human SIRPa (CD172a) (solid line) or PE-Mouse isotype control (dashed line). |
Application | FCM |
Recommended Dose | 5 μl/Test, 0.1 mg/ml |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human SIRPA / CD172A (rh SIRPA / CD172A; TMPY-01573; NP_542970.1; Met1-Arg370, Gly 75 Ala) and conjugated with PE under optimum conditions, the unreacted PE was removed. |
Purification | Protein A |
Appearance | Liquid |
Formulation | PBS solution containing 0.5% BSA and 0.1% sodium azide |
Research Background | Tyrosine-protein phosphatase non-receptor type substrate 1, also known as SHP substrate 1, Inhibitory receptor SHPS-1, Brain Ig-like molecule with tyrosine-based activation motifs, Macrophage fusion receptor, CD172 antigen-like family member A, SIRPA and CD172a, is a single-pass type I membrane protein which contains two Ig-like C1-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. SIRPA is ubiquitously expressed. It is highly expressed in brain and detected at lower levels in heart, placenta, lung, testis, ovary, colon, liver, small intestine, prostate, spleen, kidney, skeletal muscle and pancreas. It is also detected on myeloid cells, but not T-cells. SIRPA is an immunoglobulin-like cell surface receptor for CD47. SIRPA acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. SIRPA supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment. It may play a key role in intracellular signaling during synaptogenesis and in synaptic function. SIRPA is involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin. It mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: IP AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
Conjucates | PE |
Others Formats | Unconjugated/APC/FITC |
Antibody Types Available | 4 |
Immunogen | Recombinant Human SIRPA / CD172A protein (TMPY-01573) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.